INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF P38 MULTI-TRNA SYNTHETASE COMPLEX
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
1 - 125 . (canceled)
126 . A therapeutic composition, comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide selected from Table(s) 1-3, or Table(s) 4-6, and Table(s) 7-9, wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.
127 . The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.
128 . The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.
129 . The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.
130 . The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.
131 . The therapeutic composition of claim 126 , wherein the composition is a sterile, freeze-dried powder.
132 . The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.
133 . The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.
134 . The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.
135 . The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.
136 . The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.
137 . A method of modulating a cellular activity of a cell, or protein, comprising contacting the cell or protein with a therapeutic composition of claim 126 .
138 . The method of claim 137 , wherein the cellular activity is selected from cell proliferation, cell differentiation, cell signaling, gene transcription, angiogenesis, cell binding, metabolism, cytokine production or activity, cytokine receptor activity, and inflammation.
139 . The method of claim 137 , wherein the cell type is selected from the group consisting of pre-adipocytes, bone marrow, neutrophils, blood cells, hepatocytes, astrocytes, mesenchymal stem cells, and skeletal muscle cells.
140 . The method of claim 137 , wherein the cell is in a subject.
141 . The method of claim 140 , comprising treating the subject, wherein the subject has a condition associated with a neoplastic disease, an immune system disease or condition, an inflammatory disorder, an infectious disease, a metabolic disease, neuronal/neurological disease, a muscular/cardiovascular disease, a disease associated with aberrant hematopoiesis, a disease associated with aberrant angiogenesis, or a disease associated with aberrant cell survival.